Scarica l'app Stockscreener
0.8499
0.01%
-0.000100
Dopo l'orario di chiusura:
.85
0.000100
+0.01%
Pasithea Therapeutics Corp Borsa (KTTA) Ultime notizie
Pasithea Therapeutics appoints chief medical officer - MSN
Pasithea Therapeutics (KTTA) CEO awarded 1.76M stock options at $0.841 - Stock Titan
Pasithea (NASDAQ: KTTA) grants director 152,783 options at $0.841 strike - Stock Titan
Pasithea Therapeutics (KTTA) director receives 152,783 stock options grant - Stock Titan
Pasithea Therapeutics (KTTA) CFO receives 1.13M-share stock option grant - Stock Titan
[Form 4] Pasithea Therapeutics Corp. Insider Trading Activity - Stock Titan
Pasithea Therapeutics (NASDAQ: KTTA) grants director Emer Leahy 152,783 options - Stock Titan
Pasithea (KTTA) director receives 152,783 stock options at $0.841 - Stock Titan
Pasithea Therapeutics (NASDAQ: KTTA) names Chief Medical Officer as reporting insider on Form 3 - Stock Titan
Pasithea Therapeutics Appoints Dr. Kartik Krishnan as Chief Medical Officer to Advance PAS-004 MEK Inhibitor for NF1 and Rare Diseases 12 - Minichart
Pasithea Therapeutics Appoints New CMO, Updates Equity Incentives - TipRanks
New CMO and large option grants at Pasithea Therapeutics (NASDAQ: KTTA) - Stock Titan
Pasithea Therapeutics Announces Appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical Officer - Investing News Network
Pasithea names Kartik Krishnan as chief medical officer By Investing.com - Investing.com South Africa
Pasithea Therapeutics Appoints Kartik Krishnan as Chief Medical Officer - citybiz
Pasithea names Kartik Krishnan as chief medical officer - Investing.com
Is Pasithea Therapeutics (NASDAQ:KTTA) In A Good Position To Deliver On Growth Plans? - Yahoo Finance
KTTA Stock Price, Quote & Chart | PASITHEA THERAPEUTICS CORP (NASDAQ:KTTA) - ChartMill
Funicular Funds (KTTA) reports 1.84M shares, 7.4% stake in Pasithea (KTTA) - Stock Titan
KTTA Reiterated by HC Wainwright & Co. -- Price Target Maintained at $3.00 - GuruFocus
Pasithea Therapeutics Announces Grant of Rare Pediatric Disease Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 - Investing News Network
FDA grants rare pediatric disease status to Pasithea’s PAS-004 By Investing.com - Investing.com South Africa
FDA grants rare pediatric disease status to Pasithea’s PAS-004 - Investing.com
Pasithea Therapeutics Announces Grant of Rare Pediatric Disease Designation (RPDD) by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) - ChartMill
Pasithea Therapeutics (KTTA) Stock Employment Data (Grinds Lower) 2026-04-20Open Stock Signal Network - Newser
Coastlands Capital reveals KTTA (NASDAQ: KTTA) stake in shares and pre-funded warrants - Stock Titan
Form 3Initial statement of beneficial ownership of securities - ADVFN
Can Pasithea Therapeutics Corp grow without external funding2026 Momentum Check & Verified Short-Term Plans - baoquankhu1.vn
Should you buy the dip on Pasithea Therapeutics Corp2026 Weekly Recap & Stepwise Swing Trade Plans - baoquankhu1.vn
Loss Report: What is the next catalyst for Pasithea Therapeutics Corp Equity WarrantPortfolio Gains Summary & Risk Adjusted Buy/Sell Alerts - baoquankhu1.vn
Pasithea Therapeutics Corp. (KTTA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Market Wrap: Can Pasithea Therapeutics Corp grow without external funding2026 Recap & Accurate Entry and Exit Point Alerts - baoquankhu1.vn
Is Pasithea Therapeutics (KTTA) Stock Good for Passive Investors | Price at $0.76, Down 0.52%Popular Trader Picks - Newser
Opaleye/James Silverman hold 2.49M shares of Pasithea (KTTA) in Schedule 13G - Stock Titan
Aug Opening: Whats the beta of Pasithea Therapeutics Corp stockTreasury Yields & Daily Chart Pattern Signals - baoquankhu1.vn
Buyback Watch: How does Pasithea Therapeutics Corp correlate with Nasdaq2026 Outlook & Weekly Watchlist for Consistent Profits - baoquankhu1.vn
Pasithea Therapeutics Corp reports results for the quarter ended December 31Earnings Summary - TradingView
KTTA Should I Buy - Intellectia AI
Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Causing Significant Morbidity - Sahm
Trade Report: Is Pasithea Therapeutics Corp stock influenced by commodity prices2026 Biggest Moves & Technical Entry and Exit Tips - baoquankhu1.vn
Pasithea receives FDA fast track status for NF1 drug candidate By Investing.com - Investing.com Australia
Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 Associated Plexiform Neurofibromas Causing Significant Morbidity - Investing News Network
Pasithea receives FDA fast track status for NF1 drug candidate - Investing.com
Pasithea Therapeutics Announces Grant of Fast Track - GlobeNewswire
KTTA SEC FilingsPasithea Therapeutics Corp 10-K, 10-Q, 8-K Forms - Stock Titan
Signal Recap: Whats the beta of Pasithea Therapeutics Corp stockDividend Hike & Verified Entry Point Detection - baoquankhu1.vn
Pasithea Therapeutics Corp expected to post a loss of 45 cents a shareEarnings Preview - TradingView
Pasithea (NASDAQ: KTTA) highlights PAS-004 trials and NF1 focus - Stock Titan
Pasithea Therapeutics Corp. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Reviewing Pasithea Therapeutics (NASDAQ:KTTA) and Forte Biosciences (NASDAQ:FBRX) - Defense World
Can Pasithea Therapeutics Corp disrupt its industryMarket Trend Review & High Return Stock Watch Alerts - baoquankhu1.vn
Highs Report: What is the long term forecast for Pasithea Therapeutics Corp stockQuarterly Market Summary & Low Drawdown Investment Ideas - baoquankhu1.vn
Vericel (NASDAQ:VCEL) versus Pasithea Therapeutics (NASDAQ:KTTA) Critical Review - Defense World
Can Pasithea Therapeutics Corp sustain earnings growth2026 Chart Watch & High Yield Stock Recommendations - baoquankhu1.vn
Positive Signs As Multiple Insiders Buy Pasithea Therapeutics Stock - simplywall.st
1.77%
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):